A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ADAURA
- Sponsors AstraZeneca
- 21 Aug 2017 Planned End Date changed from 21 Jul 2021 to 10 Dec 2021.
- 21 Aug 2017 Planned primary completion date changed from 21 Jul 2021 to 10 Dec 2021.
- 10 Jun 2017 Biomarkers information updated